Morning Overview on MSN
The FDA approved the first gene therapy for sickle cell in children as young as two
Regulators have opened a one-time gene therapy to some of the youngest patients with sickle cell disease. On July 1, 2026, ...
The FDA expanded access to gene therapy for sickle cell disease, allowing children as young as 2 to receive the breakthrough ...
Learn how gene editing is transforming sickle cell disease treatment and why expanding access to younger children matters.
A Nashville doctor helped pioneer an FDA approved "state-of-the-art" gene-editing therapy that could be a cure for painful ...
FDA expands Casgevy CRISPR gene therapy to children aged 2+ with sickle cell disease and beta thalassemia, enabling earlier ...
Gene editing has delivered remarkable results against sickle cell disease. Now researchers are working to make these ...
Recent data published in NEJM demonstrates that CRISPR gene-editing therapy achieves complete clinical efficacy endpoints in ...
The expanded indication lowers the eligible age from 12 to 2 years old for the autologous genome edited gene therapy following successful phase 3 trials in children. The Food and Drug Administration ...
TAMPA, FL, UNITED STATES, April 30, 2026 /EINPresswire.com/ — San Rocco Therapeutics (SRT) today announced two abstracts at the upcoming 2026 ASGCT Annual Meeting ...
Stem cell transplantation (also called bone marrow transplantation) and gene therapy are among the most powerful curative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results